These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 35272497)

  • 1. Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.
    Jin J; Wang R; Yang J; Hu H; Wang D; Cai L; Fang Z; Dong S; Hu S; Wang Y; Liu B
    Hum Gene Ther; 2022 Jun; 33(11-12):649-663. PubMed ID: 35272497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical safety assessment of an oncolytic herpes simplex virus type 2 expressed PD-L1/CD3 bispecific antibody.
    Wang Y; Wang R; Hu H; Jin J; Cai L; Zhang S; Yi F; Li Y; Zheng Z; Zhou Q; Fang Z; Liu B
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110975. PubMed ID: 37757634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
    Zhang J; Guo Y; Fang H; Guo X; Zhao L
    Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors.
    Wang Y; Jin J; Li Y; Zhou Q; Yao R; Wu Z; Hu H; Fang Z; Dong S; Cai Q; Hu S; Liu B
    Transl Res; 2022 Feb; 240():64-86. PubMed ID: 34757194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb.
    Zhang Z; Yang N; Lu H; Chen Y; Xu L; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhang W; Yang H; Peng X; Zhou L; Tong A
    Cancer Lett; 2024 Apr; 588():216760. PubMed ID: 38428724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology.
    Cai L; Hu H; Duan H; Li Y; Zou Z; Luo K; Zhang Z; Yang J; Jin J; Chen Y; Ke Z; Fang Z; Liu Q; Hong X; Hu S; Liu B
    J Med Virol; 2020 Dec; 92(12):3617-3627. PubMed ID: 31994741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.
    Shi N; Zhou Y; Liu Y; Zhang R; Jiang X; Ren C; Gao X; Luo L
    Front Immunol; 2022; 13():1047610. PubMed ID: 36518768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
    Park JA; Cheung NV
    J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.
    Zhao Q; Zhang W; Ning Z; Zhuang X; Lu H; Liang J; Li J; Zhang Y; Dong Y; Zhang Y; Zhang S; Liu S; Liu B
    PLoS One; 2014; 9(3):e93103. PubMed ID: 24671154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
    Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
    Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
    Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.
    Li HY; Chen YL; Deng XN; Li HH; Tan J; Liu GJ; Zheng YJ; Pei M; Peng KT; Yue LL; Chen XJ; Liu Y; Zhao YS; Wang CH
    Acta Pharmacol Sin; 2023 Nov; 44(11):2322-2330. PubMed ID: 37328649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
    Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
    Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells.
    Chen YJ; Chen M; Cheng TL; Tsai YS; Wang CH; Chen CY; Wu TY; Tzou SC; Wang KH; Cheng JJ; Kao AP; Lin SY; Chuang KH
    J Biomed Sci; 2023 May; 30(1):35. PubMed ID: 37259079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
    Mei S; Peng S; Vong EG; Zhan J
    Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo.
    Yin L; Zhao C; Han J; Li Z; Zhen Y; Xiao R; Xu Z; Sun Y
    Ther Clin Risk Manag; 2017; 13():117-130. PubMed ID: 28223815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1.
    Zhu Y; Hu X; Feng L; Yang Z; Zhou L; Duan X; Cheng S; Zhang W; Liu B; Zhang K
    Mol Ther Oncolytics; 2019 Dec; 15():201-213. PubMed ID: 31788554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
    Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy.
    Chen YL; Cui Y; Liu X; Liu G; Dong X; Tang L; Hung Y; Wang C; Feng MQ
    J Biol Chem; 2021 Dec; 297(6):101420. PubMed ID: 34798072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.